STOCK TITAN

Apellis Pharmaceuticals, Inc. - APLS STOCK NEWS

Welcome to our dedicated page for Apellis Pharmaceuticals news (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmaceuticals stock.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutic compounds. The company's primary focus is on treating diseases with high unmet medical needs through the inhibition of the complement system, a crucial part of the immune system. Apellis targets the complement system at the level of C3, aiming to provide comprehensive disease control.

Apellis's flagship products include SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan). SYFOVRE is the first-ever approved therapy for geographic atrophy (GA), a leading cause of blindness, while EMPAVELI is approved for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare hematological disease. Both medicines reflect the company's innovative approach to complement immunotherapy.

In 2023, Apellis achieved significant milestones, including generating $397 million in revenue, with substantial contributions from SYFOVRE and EMPAVELI. The company has also presented positive data from its Phase 2 NOBLE study for systemic pegcetacoplan in rare kidney diseases at the European Renal Association Congress, highlighting the potential of pegcetacoplan to address complex medical conditions.

Looking ahead, Apellis anticipates regulatory developments, including the European Medicines Agency’s (EMA) review of the marketing authorization application (MAA) for SYFOVRE and the expected topline data from the Phase 3 VALIANT study of systemic pegcetacoplan in mid-2024. Financially robust, Apellis recently closed a $375 million funding deal with Sixth Street to buy out existing liabilities, significantly improving its liquidity profile and positioning the company for sustainable growth.

Apellis's commitment to advancing science is evident through its extensive pipeline and collaborations, such as its partnership with Sobi for systemic pegcetacoplan. The company's approach combines bold scientific endeavors with compassionate patient care, continually striving to bring life-changing therapies to those in need.

Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) has appointed Peter Hillmen, a prominent hematologist, as the head of hematology engagement, effective May 23, 2022. Hillmen brings decades of expertise in paroxysmal nocturnal hemoglobinuria (PNH), having developed treatments including EMPAVELI (pegcetacoplan). His role will focus on expanding collaborations with U.S. hematology leaders and enhancing Apellis' initiatives. EMPAVELI is positioned as a potential new standard of care for PNH, demonstrating superior effectiveness compared to existing therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
none
-
Rhea-AI Summary

Apellis Pharmaceuticals (APLS) reported promising long-term results from the Phase 3 DERBY and OAKS studies for pegcetacoplan, a targeted C3 therapy, showing significant reductions in geographic atrophy (GA) lesion growth after 18 months.

Monthly and every-other-month treatments led to reductions of up to 33% for extrafoveal lesions and 19% for foveal lesions (p<0.0001). This positions pegcetacoplan as a potential first treatment for GA, a leading cause of blindness affecting over 5 million globally. Apellis plans to submit a New Drug Application to the FDA in Q2 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
-
Rhea-AI Summary

Apellis Pharmaceuticals, a leader in complement medicine, will host a conference call and webcast on May 4, 2022, at 4:30 p.m. ET to discuss its first quarter 2022 financial results. The live call can be accessed by pre-registering online, and a replay will be available for 30 days. The company is committed to delivering transformative therapies for rare, retinal, and neurological diseases, highlighted by the launch of the first new class of complement medicine in 15 years with its targeted C3 therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.99%
Tags
conferences earnings
-
Rhea-AI Summary

Apellis Pharmaceuticals, a biopharmaceutical leader in complement therapies, will present at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 3:00 p.m. ET. The conference format will be virtual, and interested parties can access the live webcast on the company’s website under the 'Events and Presentations' section. A replay will be available for 90 days post-event. This presentation highlights Apellis's commitment to innovation in treatments for rare and neurological diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.11%
Tags
conferences
-
Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) announced the completion of an underwritten public offering of common stock, raising $402.5 million. This includes the full exercise of underwriters' options to purchase an additional 1,117,021 shares at $47.00 each, totaling 8,563,830 shares sold. Proceeds will fund operations and capital expenses through Q1 2024, alongside existing cash and revenue from EMPAVELI® sales and milestone payments from Sobi. The offering was conducted under an effective shelf registration statement filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
Rhea-AI Summary

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced the pricing of a public offering of 7,446,809 shares of common stock at $47.00 per share, aiming for total gross proceeds of $350 million, before deductions. The offering, expected to close on March 28, 2022, includes a 30-day option for underwriters to purchase an additional 1,117,021 shares. The shares will be sold under a shelf registration statement filed with the SEC. Leading financial firms J.P. Morgan, Goldman Sachs, and Evercore are managing the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.24%
Tags
-
Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq:APLS) has announced a public offering of $300 million in common stock, with an additional 15% option for underwriters. The offering is underwritten by J.P. Morgan, Goldman Sachs, and Evercore. This initiative is part of their ongoing strategy to leverage capital for future growth. The offering aligns with a previously filed SEC registration statement. It emphasizes Apellis' commitment to advancing therapies in complement medicine, particularly for rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.24%
Tags
-
Rhea-AI Summary

Apellis Pharmaceuticals (APLS) released positive data from the Phase 3 DERBY and OAKS studies, showcasing that intravitreal pegcetacoplan effectively reduces geographic atrophy (GA) lesion growth after 18 months. Both monthly and every-other-month treatments demonstrated significant efficacy with p-values below 0.05. The favorable safety profile was maintained, with low rates of infections. These results will support a New Drug Application (NDA) submission to the FDA planned for Q2 2022, with a conference call scheduled for today to discuss findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.96%
Tags
Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) announced participation in two upcoming investor conferences in March 2022. The Cowen 42nd Annual Health Care Conference will feature a fireside chat on March 9, 2022, at 12:50 p.m. ET, while the Oppenheimer 32nd Annual Healthcare Conference will take place on March 16, 2022, at 12:40 p.m. ET. Both events will be accessible via live webcast on the company’s website, with replays available for 90 days post-event. Apellis focuses on innovative therapies for diseases linked to the complement system.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
conferences

FAQ

What is the current stock price of Apellis Pharmaceuticals (APLS)?

The current stock price of Apellis Pharmaceuticals (APLS) is $33.21 as of December 23, 2024.

What is the market cap of Apellis Pharmaceuticals (APLS)?

The market cap of Apellis Pharmaceuticals (APLS) is approximately 4.1B.

What does Apellis Pharmaceuticals, Inc. specialize in?

Apellis specializes in the discovery, development, and commercialization of novel therapeutic compounds aimed at treating diseases with high unmet medical needs through the inhibition of the complement system.

What are Apellis's primary products?

Apellis's primary products are SYFOVRE® (pegcetacoplan injection) for geographic atrophy and EMPAVELI® (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH).

How did Apellis perform financially in 2023?

In 2023, Apellis generated $397 million in revenue, with significant contributions from SYFOVRE and EMPAVELI.

What is SYFOVRE® approved for?

SYFOVRE® is approved for the treatment of geographic atrophy (GA), a leading cause of blindness related to age-related macular degeneration.

What is EMPAVELI® approved for?

EMPAVELI® is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the United States, European Union, and other countries globally.

What recent clinical data has Apellis presented?

Apellis recently presented positive data from its Phase 2 NOBLE study for systemic pegcetacoplan in treating C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) at the European Renal Association Congress.

What is the latest financial development for Apellis?

Apellis recently closed a $375 million funding deal with Sixth Street to buy out existing SFJ Pharmaceuticals development liabilities, significantly improving its liquidity profile.

What are Apellis's expectations for 2024?

In 2024, Apellis anticipates regulatory developments from EMA and expects topline data from the Phase 3 VALIANT study for systemic pegcetacoplan in mid-2024.

Who is Apellis collaborating with for systemic pegcetacoplan?

Apellis is collaborating with Sobi for the global co-development and commercialization of systemic pegcetacoplan.

How is Apellis combining science and patient care?

Apellis combines bold scientific endeavors with compassionate patient care, striving to bring life-changing therapies to patients with serious diseases.

Apellis Pharmaceuticals, Inc.

Nasdaq:APLS

APLS Rankings

APLS Stock Data

4.11B
105.50M
13.98%
99.97%
18.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WALTHAM